TY - JOUR
T1 - Neurotrophin-3 (NT-3) as a Potential Biomarker of the Peripheral Nervous System Damage Following Breast Cancer Treatment
AU - Tonyan, Samvel
AU - Pospelova, Maria
AU - Krasnikova, Varvara
AU - Fionik, Olga
AU - Alekseeva, Tatyana
AU - Samochernykh, Konstantin
AU - Ivanova, Nataliya
AU - Vavilova, Tatyana
AU - Vasilieva, Elena
AU - Makhanova, Albina
AU - Nikolaeva, Aleksandra
AU - Bukkieva, Tatyana
AU - Combs, Stephanie
AU - Shevtsov, Maxim
N1 - Publisher Copyright:
© 2023 by the authors.
PY - 2023/6
Y1 - 2023/6
N2 - Damage to the peripheral nervous system (PNS) is a common complication of breast cancer (BC) treatment, with 60 to 80% of breast cancer survivors experiencing symptoms of PNS damage. In the current study, the levels of brain-derived neurotrophic factor (BDNF), galectin-3 (Gal-3), and neurotrophin-3 (NT-3) were measured in the blood serum of BC patients by ELISA as potential biomarkers that might indicate the PNS damage. Sixty-seven patients were enrolled in this multi-center trial and compared to the aged-matched healthy female volunteers (control group) (n = 25). Intergroup comparison of biomarker levels (i.e., Gal-3 and BDNF) did not show significant differences in any of the studied subgroups. However, intriguingly, NT-3 levels were significantly higher in BC patients as compared to healthy volunteers, constituting 14.85 [10.3; 18.0] and 5.74 [4.56; 13.7] pg/mL, respectively (p < 0.001). In conclusion, NT-3 might be employed as a potential biomarker in BC patients with clinical manifestations of PNS damage. However, further studies to validate its correlation to the degree of peripheral nervous system lesions are of high value.
AB - Damage to the peripheral nervous system (PNS) is a common complication of breast cancer (BC) treatment, with 60 to 80% of breast cancer survivors experiencing symptoms of PNS damage. In the current study, the levels of brain-derived neurotrophic factor (BDNF), galectin-3 (Gal-3), and neurotrophin-3 (NT-3) were measured in the blood serum of BC patients by ELISA as potential biomarkers that might indicate the PNS damage. Sixty-seven patients were enrolled in this multi-center trial and compared to the aged-matched healthy female volunteers (control group) (n = 25). Intergroup comparison of biomarker levels (i.e., Gal-3 and BDNF) did not show significant differences in any of the studied subgroups. However, intriguingly, NT-3 levels were significantly higher in BC patients as compared to healthy volunteers, constituting 14.85 [10.3; 18.0] and 5.74 [4.56; 13.7] pg/mL, respectively (p < 0.001). In conclusion, NT-3 might be employed as a potential biomarker in BC patients with clinical manifestations of PNS damage. However, further studies to validate its correlation to the degree of peripheral nervous system lesions are of high value.
KW - BDNF
KW - brain-derived neurotrophic factor
KW - breast cancer
KW - chemotherapy-induced peripheral neuropathy
KW - galectin-3
KW - mastectomy
KW - neuropathy
KW - neurotrophin-3
KW - peripheral nervous system
KW - postmastectomy pain syndrome
KW - radiation-induced peripheral neuropathy
UR - http://www.scopus.com/inward/record.url?scp=85163641408&partnerID=8YFLogxK
U2 - 10.3390/pathophysiology30020010
DO - 10.3390/pathophysiology30020010
M3 - Article
AN - SCOPUS:85163641408
SN - 0928-4680
VL - 30
SP - 110
EP - 122
JO - Pathophysiology
JF - Pathophysiology
IS - 2
ER -